Health care stocks exploded in 2013, but a few leading medical device stocks in particular hit the jackpot in the market's rally. Cardiac device leader Boston Scientific (NYSE:BSX) saw its stock more than double last year, while rival St. Jude Medical (NYSE:STJ) roared higher by more than 70%. However, sales of mainstay devices such as defibrillators and pacemakers continue to lag, with pricing pressure and tough competition weighing on leading companies in the industry.
Can 2014 bring a turnaround for the cardiac device industry's finances -- and keep these stocks charged with momentum? New areas of innovation such as renal denervation and atrial fibrillation have investors in companies such as Medtronic (NYSE:MDT) and St. Jude excited, while new markets, such as China, are ripe for inroads.
Will that pay off for investors? In the video below, Motley Fool contributor Dan Carroll details whether forward-looking moves by Boston Scientific and other top cardiac device stocks will translate to rising earnings and a stronger industry outlook -- and how you can make money off of the future of these top picks.
Have you jump-started your financial future?
Stocks have been on a roll lately, but millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.